HomeBUSINESS
BUSINESS

Gilead Seeks Japan Approval for Epclusa
(May.16.2018)

Gilead Sciences said on May 15 that it has filed for Japan approval of a fixed-dose combo of sofosbuvir/velpatasvir (SOF/VEL), otherwise known as Epclusa overseas, for the treatment of decompensated cirrhosis and for hepatitis C in patients who failed in direct-acting antivirals (DAAs) ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar